|
| 36306483 | Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. | J Clin Oncol | 2023 |
| 37619846 | Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials. | Ann Oncol | 2023 |
| 37539667 | Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. | Int J Cancer | 2023 |
| 37459754 | Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. | J Clin Oncol | 2023 |
| 37379691 | A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. | J Clin Oncol | 2023 |
| 37339926 | Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer. | Cancer Control | 2023 |
| 37339254 | Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. | Oncologist | 2023 |
| 36780583 | Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer. | JCO Oncol Pract | 2023 |
| 34505880 | Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. | J Natl Cancer Inst | 2022 |
| 35963480 | Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance]. | Ann Oncol | 2022 |
| 36056231 | Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. | Target Oncol | 2022 |
| 35984985 | Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 35952316 | Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. | JCO Precis Oncol | 2022 |
| 35285484 | N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. | Oncologist | 2022 |
| 35279470 | Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials. | Eur J Cancer | 2022 |
| 32835356 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34â¿¿640 Patients in the ACCENT Database. | J Natl Cancer Inst | 2021 |
| 33646489 | Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). | Invest New Drugs | 2021 |
| 33634324 | A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. | Cancer Chemother Pharmacol | 2021 |
| 34794066 | A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. | Eur J Cancer | 2021 |
| 34485815 | Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. | JNCI Cancer Spectr | 2021 |
| 34778691 | FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. | JCO Precis Oncol | 2021 |
| 33934058 | Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). | Eur J Cancer | 2021 |
| 34149004 | Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). | Pharmacogenet Genomics | 2021 |
| 33972368 | Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33341444 | Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. | Eur J Cancer | 2021 |
| 33338878 | The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. | Transl Oncol | 2021 |
| 33356421 | Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. | J Clin Oncol | 2021 |
| 33203692 | Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). | Cancer Epidemiol Biomarkers Prev | 2021 |
| 32455336 | Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. | JNCI Cancer Spectr | 2020 |
| 32085892 | Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. | Ann Oncol | 2020 |
| 31811950 | Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. | Clin Gastroenterol Hepatol | 2020 |
| 31804393 | Is There a Role for Liver Transplantation in the Treatment of Patients With Metastatic Colorectal Cancer? | Ann Surg | 2020 |
| 31826977 | Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. | Oncologist | 2020 |
| 31941061 | Molecular Classification of Gastric Cancer among Alaska Native People. | Cancers (Basel) | 2020 |
| 31759906 | Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. | Pancreatology | 2020 |
| 33222443 | Collateral damage of COVID-19 pandemic on oncology clinical trials. | Chin Clin Oncol | 2020 |
| 32923882 | Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. | JCO Precis Oncol | 2020 |
| 32172199 | Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. | Eur J Cancer | 2020 |
| 32201506 | Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). | Ther Adv Med Oncol | 2020 |
| 30301825 | Intertumoral Heterogeneity of CD3<sup>+</sup> and CD8<sup>+</sup> T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. | Clin Cancer Res | 2019 |
| 31893488 | Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. | Ann Oncol | 2019 |
| 30217513 | Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. | Clin Gastroenterol Hepatol | 2019 |
| 31183212 | Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. | J Gastrointest Oncol | 2019 |
| 31268130 | Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. | Ann Oncol | 2019 |
| 30973464 | Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort. | Pancreas | 2019 |
| 30679315 | A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). | Oncologist | 2019 |
| 30266490 | Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. | HPB (Oxford) | 2019 |
| 30623420 | Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). | Int J Cancer | 2019 |
| 29348486 | Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. | Br J Cancer | 2018 |
| 29991877 | Gastric cancer in Alaska Native people: A cancer health disparity. | World J Gastroenterol | 2018 |